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Abstract
Summary In this observational study in postmenopausal
women with severe osteoporosis, the incidence of fractures
was decreased during 18 months of teriparatide treatment
with no evidence of further change in the subsequent 18-
month post-teriparatide period when most patients took
other osteoporosis medications. Fracture reduction was
accompanied by reductions in back pain.
Introduction To describe fracture outcomes and back pain
in postmenopausal women with severe osteoporosis during
18 months of teriparatide treatment and 18 months post-
teriparatide in normal clinical practice.
Methods The European Forsteo Observational Study
(EFOS) was a prospective, multinational, observational
study. Data on incident clinical fractures and back pain
(100 mm Visual Analogue Scale [VAS] and questionnaire)
were collected. Fracture data were summarised in 6-month
intervals and analysed using logistic regression with
repeated measures. Changes from baseline in back pain
VAS were analysed using a repeated measures model.
Results A total of 208 (13.2%) of 1,576 patients sustained
258 fractures during 36 months of follow-up: 34% were
clinical vertebral fractures and 66% non-vertebral fractures.
The adjustedoddsoffracturewerereducedduringteriparatide
treatment and there was no evidence of further change in the
18-month post-teriparatide period, during which 63.3%
patients took bisphosphonates. A 74% decrease in the
adjusted odds of fracture in the 30- to <36-month period
compared with the first 6-month period was observed (p<
0.001). Back pain decreased during teriparatide treatment
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DOI 10.1007/s00198-010-1498-5and this decrease was sustained after teriparatide discontin-
uation. Adjusted mean back pain VAS decreased by
26.3 mm after 36 months (p<0.001) from baseline mean of
57.8 mm.
Conclusions In a real-life clinical setting, the risk of
fracture decreased during teriparatide treatment, with no
evidence of further change after teriparatide was discon-
tinued. The changes in back pain seen during treatment
were maintained for at least 18 months after teriparatide
discontinuation. These results should be interpreted in the
context of the design of an observational study.
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Introduction
Postmenopausal women with osteoporosis have an in-
creased risk of fracture and its associated complications,
such as back pain and disability/functional impairment,
which can lead to a reduced health-related quality of life
(HRQoL) [1–9]. Clinical vertebral and hip fractures are also
associated with increased mortality [10, 11]. Treatment
aims to reduce the risk, incidence and burden of
osteoporosis-related fractures.
Teriparatide, a recombinant human N-terminal fragment
of parathyroid hormone (rhPTH 1–34), is a bone anabolic
agent that increases bone mass and strength. In a placebo-
controlled trial, daily teriparatide treatment for 19 months
reduced the risk of vertebral and non-vertebral fractures in
postmenopausal women with severe osteoporosis [12].
Teriparatide is approved for a limited treatment duration
and is typically used as a second-line treatment option in
postmenopausal women with severe osteoporosis. Thus,
many patients receiving teriparatide have previously been
treated with antiresorptive therapies and require further
osteoporosis medication after teriparatide is discontinued.
However, there is limited published data on the use of
teriparatide as a sequential treatment for osteoporosis,
particularly in a real-life clinical practice setting.
Most previous studies reporting the effects of teriparatide
in postmenopausal women have been controlled clinical
trials with strict inclusion criteria and highly selected
patient populations; patients with co-morbidities, such as
rheumatoid arthritis, and those taking concomitant medi-
cations are often excluded. It has been estimated that about
80% of patients receiving treatment for osteoporosis would
not be eligible for inclusion in a randomised controlled trial
[13]. Since observational studies have few exclusion
criteria, they can investigate treatment effects in a broader
range of patients in the routine care setting, and can provide
valuable supporting information that is applicable in
clinical practice [14]. No previous observational studies
have examined the effectiveness and safety of teriparatide
during and after treatment.
The European Forsteo Observational Study (EFOS) was
a 36-month, prospective, observational study designed to
evaluate fracture outcomes, back pain and HRQoL in
postmenopausal women with severe osteoporosis treated
with teriparatide in the outpatient setting for a maximum of
18 months, followed by a post-teriparatide treatment period
of a further 18 months. We report here the main study
analyses for the total study cohort followed up for
36 months, i.e., the incidence of clinical vertebral and
non-vertebral fractures and changes in back pain, both
during teriparatide treatment and in the 18 months after
teriparatide discontinuation. The changes in fracture risk,
back pain and HRQoL during 18 months of teriparatide
treatment in EFOS have been previously reported [15].
Methods
Study design and patients
The study design and characteristics of the EFOS patient
population have been described previously [16]. Briefly,
1,649 postmenopausal women with a diagnosis of osteo-
porosis who were about to initiate teriparatide treatment
were enrolled in eight European countries (Austria, Den-
mark, France, Germany, Greece, Ireland, the Netherlands,
and Sweden). Patients were followed for the duration of
their teriparatide treatment, which they could discontinue at
any time, and were asked to return for two additional visits
after they discontinued teriparatide. Patients were not
included if they were currently being treated with an
investigational drug or procedure, or had any contra-
indications as described in the teriparatide label. Because
this was an observational study, there were no further
restrictions for the selection of patients. Patients gave
written informed consent prior to enrolment and were able
to withdraw without consequence at any time. The study
was approved by local ethics committees or review boards,
depending on local requirements.
Data collection
At the baseline visit, patient demographic characteristics,
risk factors for osteoporosis and falls, osteoporosis thera-
pies and disease status were recorded [16]. The women
attended visits at baseline and at approximately 3, 6, 12 and
18 months after teriparatide initiation, and at 6 and
18 months after discontinuing teriparatide treatment.
Incident clinical vertebral and non-vertebral fractures,
the primary study endpoint, were diagnosed and confirmed
by review of the original X-rays and/or the radiology or
2710 Osteoporos Int (2011) 22:2709–2719surgical reports at the investigational site. A new or
worsened vertebral fracture was defined from the presence
of a confirmed radiographic vertebral fracture associated
with signs and/or symptoms, such as acute or severe back
pain, suggestive of a vertebral fracture [17].
Back pain was self-assessed by patients at each visit
using a back pain questionnaire detailing frequency and
severity in the past month, limitations of activities and days
in bed due to back pain [15]. Patients also rated their back
pain severity using a horizontal 100 mm visual analogue
scale (VAS), ranging from 0 mm (no back pain) to 100 mm
(worst possible back pain). This type of VAS is reliable and
reproducible for the measurement of pain [18].
Spontaneously reported adverse events were collected
throughout the study.
Statistical analysis
Data were analysed for the total study cohort, which
included all patients with a baseline visit and at least one
follow-up visit. In addition, the post-teriparatide cohort
included those patients who discontinued teriparatide and
had at least one post-teriparatide follow-up visit.
Results for the active treatment period have already been
published [15].
Descriptive statistics were used to describe the study
population.
The number of fractures occurring in patients was
summarised in 6-month intervals. A logistic regression
with repeated measures was used to assess the change in
number of patients with one or more fractures over time
[19, 20]. In contrast to survival analysis, where the hazard
of the first fracture is presented, logistic regression is an
analysis of the odds of fracture (e.g., ratio of patients who
fracture versus patients who do not fracture). Patients were
included in the model at all observed intervals, regardless
of whether or not they fractured during a previous interval.
The repeated observations of each patient were assumed to
be related but no further assumptions were made about the
relationship. Unadjusted and adjusted models were per-
formed including age, prior bisphosphonate use and a
history of fracture in the last 12 months before starting
teriparatide. Contrasts were made between the odds of
fracture in the first 6 months of treatment (0 to <6 months)
and each subsequent 6-month period. Fracture modelling
was repeated for all vertebral, all non-vertebral and main
non-vertebral (forearm/wrist, hip, humerus, leg and ribs)
fractures.
Back pain VAS changes from baseline were analysed
using a mixed model for repeated measures (MMRM)
adjusting for back pain VAS at baseline, number of
previous fractures, age, diagnosis of rheumatoid arthritis,
duration of prior bisphosphonate therapy, and a history of
fracture in the 12 months before entering the study. The p
values represent the unique influence of the corresponding
factor after adjustment for all other factors in the model.
The number of patients reporting an improvement or
worsening in the severity, frequency, limitation of activities
and number of days in bed (≤2 days: no change) due to
back pain was analysed using the sign test.
Results
Patient disposition and characteristics
Figure 1 summarises the patient flow through the study and
the number of patients with observations at each visit for the
total study cohort and the post-teriparatide cohort. Overall,
1,581 patients were analysed at baseline and returned for at
least one post-baseline visit; this constitutes the total study
cohort. As this was an observational study with data
collection occurring within the normal course of clinical
care, some patients missed subsequent targeted data collec-
tion visits (as detailed in Fig. 1) but returned for a later visit.
Moreover, at each time point, no further data were available
for some patients (i.e., these patients discontinued or were
lost to follow-up). The baseline characteristics of the total
study cohort are summarised in Table 1.
Teriparatide treatment
The median duration of teriparatide treatment was 541 days
(Q1, Q3: 432, 552 days) for the total study cohort and
545 days (Q1, Q3: 533, 553 days) for the subset of patients
in the post-teriparatide cohort (n=909). Persistence with
teriparatide treatment is shown in Fig. S1.
The main reasons for discontinuation of teriparatide in the
total study cohort were treatment completed (n=871; 77.9%),
patient decision (n=120; 10.7%), adverse event (n=85;
7.6%), physician decision (n=30; 2.7%), death (n=12;
1.1%) and non-compliance (n=5; 0.4%).
Osteoporosis medication after teriparatide
Of the 907 patients with data available on osteoporosis
medication taken after teriparatide was discontinued, 70.7%
took an antiresorptive drug, mainly bisphosphonates
(63.3%). The drugs most commonly taken at some point
after stopping teriparatide were alendronate (32.1%),
risedronate (20.0%), raloxifene (6.1%) and calcitonin
(4.2%). Most patients also took calcium (84.5%) and
vitamin D (86.2%). Supplementary data available for 676
patients showed that 5.0% received strontium ranelate after
stopping teriparatide and two patients received full-length
parathyroid hormone (rhPTH1-84).
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Table 2 shows the incidence of fractures during and after
teriparatide treatment for the total study cohort. Of these
1,581 women, 208 (13.2%) sustained a total of 258 clinical
fractures during the 36-month follow-up. Of the 208
women with fractures, 170 sustained a single fracture and
38 sustained two or more fractures. Of the 258 fractures, 87
(33.7%) were clinical vertebral fractures and 171 (66.3%)
were non-vertebral fractures; 129 (50.0%) of all fractures
were main non-vertebral fractures at the forearm/wrist (n=
41), hip (n=27), humerus (n=21), leg (n=21) and ribs (n=
19). The number of fractures/10,000 patient years was
highest in the first 6 months and decreased in each
subsequent 6-month interval (Table 2).
Figure 2 presents the adjusted odds of fracture (95%
confidence interval [CI]) by fracture type for each 6-month
interval in the total study cohort (adjusted by age, prior
bisphosphonate use and history of fracture in the 12 months
before starting teriparatide). For all fractures and for vertebral
fractures, there was a significant reduction in the adjusted
odds of fracture at 12 to <18 months of teriparatide treatment
and during the post-teriparatide intervals compared with the
first 6 months of teriparatide treatment. For all fractures,
there was a 74% decrease in the adjusted odds of fracture in
the 30- to <36-month period compared with 0 to <6 months
(p<0.001). The odds of having a non-vertebral fracture were
significantly lower during the 24- to <30-month interval (OR
0.40, 95% CI 0.21 to 0.75) and 30- to <36-month interval
(OR 0.41, 95% CI 0.22 to 0.76), compared with the first
6 months of teriparatide treatment. Similar results were
observed for the main non-vertebral fractures.
After adjusting for the other relevant risk factors,
patients who had a fracture in the 12 months before
baseline were more likely to fracture during the study than
patients without a fracture in the 12 months before baseline
(119 [15.6%] of 761 patients and 89 [10.9%] of 815
patients, respectively, experienced a fracture during the
study): adjusted OR 1.39 (95% CI 1.05–1.83). In addition,
patients who used bisphosphonates prior to teriparatide
were more likely to fracture during the study than those
without prior bisphosphonate use (169 [14.6%] of 1,161
patients and 39 [9.3%] of 420 patients, respectively,
experienced a fracture during the study): adjusted OR
1.64 (95% CI 1.16–2.33) for main non-vertebral fractures
(also significant for all fractures and all non-vertebral
fractures).
In a sensitivity analysis of only those patients who
completed the 36-month follow-up (n=991, 62.7% of total
study cohort), which contained 91% of the total fractures
and 73.1% of the total women with an incident clinical
fracture during the 36-month follow-up, the results were
Postmenopausal women 
enrolled 
(n=1649)
Total Study Cohort
Baseline (n=1581)
3 months (n=1483)
Missed visit (n=98)
6 months (n=1429)
Missed visit (n=70)
12 months (n=1340)
Missed visit (n=87)
18 months (n=1299)
Missed visit (n=44)
24 months (n=1103)
Missed visit (n=84)
36 months (n=1006)
No follow-up visit (n=68)
Teriparatide 
treatment for 
up to 18 
months
Teriparatide 
discontinued
Post-teriparatide Cohort
Discontinued  treatment 
(n=909)
6 months follow-up (n=847)
Missed visit (n=62)
18 months follow-up (n=812) 18 months follow-up (n=812)
No more data (n=82)
Total study cohort: all patients with a baseline visit and at least one post-baseline visit
Post-teriparatide cohort: patients who discontinued teriparatide (regardless of time) and had at least one post-treatment follow-up visit
No more data (n=72)
No more data (n=84)
No more data 
(n=156)
No more data 
(n=181)
No more data 
(n=97)
Fig. 1 Study flow and disposition of patients in the total study cohort and post-teriparatide cohort
2712 Osteoporos Int (2011) 22:2709–2719similar to those for the total study cohort given in Table 2
(data not shown).
Back pain
The mean (SD) back pain VAS at baseline was 57.8 (26.6) for
the total study cohort. Figure 3 shows the adjusted mean
change in back pain VAS from baseline over time. The
decrease in pain seen during the 18 months of teriparatide
treatment was maintained during the 18 months after
teriparatide was discontinued. Of the variables included in
the MMRM, three had a significant effect on the change in
back pain VAS: each additional 5 mm in baseline VAS was
associated with a greater improvement in back pain of
Characteristic Total study cohort
Caucasian,% 99.2
Age, years 71.0 (8.4)
Years since menopause 24.8 (9.0)
Early menopause (<40 years of age),% 8.9
Surgical menopause,% 18.7
Nulliparous,% 13.1
BMI, kg/m
2 25.1 (4.3)
Current smoker,% 13.0
Hip fracture in mother,% 20.8
Number of previous fractures after 40 years of age 2.9 (2.0)
Time since most recent fracture, years
a 2.1 (3.4)
At least one fracture in 12 months prior to study entry,% 48.4
Prior osteoporosis medication,% 92.3
Prior bisphosphonate use,% 73.4
Co-morbidities,%
b 32.5
Rheumatoid arthritis 11.9
Chronic obstructive pulmonary disease 8.7
Diabetes mellitus 5.5
Concomitant medications,%
b 63.8
Antihypertensives 37.2
Glucocorticoids 14.8
Thyroid hormone 13.3
Lumbar spine BMD, T score −3.26 (1.16)
Total hip BMD, T score −2.61 (1.05)
Table 1 Baseline characteristics
of total study cohort (n=1,581)
Data are presented as mean (SD)
unless indicated otherwise
aMedian: 0.7 years. Q1–Q3, 0.2–
2.4
bThe three most frequently used
are listed
Table 2 Incident clinical fractures during teriparatide treatment (0 to <18 months) and after discontinuation of teriparatide (18 to <36 months) for
the total study cohort
Time interval
(months)
N (missing/
unknown)
No. of fractures
per 10,000 patient years
Total number
of fractures
Patients with ≥1
fracture, n (%)
a
Odds ratio
b,c
(95% CI)
p value
0 to <6 1,581 (5) 1,119 86 76 (4.8)
6 to <12 1,475 (2) 815 58 51 (3.5) 0.706 (0.497–1.003) 0.052
12 to <18 1,371 (1) 645 43 41 (3.0) 0.609 (0.413–0.899) 0.013
18 to <24 1,271 (2) 606 36 34 (2.7) 0.547 (0.361–0.828) 0.004
24 to <30 1,109 (4) 387 20 18 (1.6) 0.331 (0.197–0.559) <0.001
30 to <36 991 (0) 327 15 13 (1.3) 0.265 (0.147–0.478) <0.001
Total 1,581 (5) 258 208 (13.2)
N=number of patients included in the observation
aAs some patients experienced a fracture in more than one time interval, the total was not the sum of patients with a fracture in each interval
bAdjusted model by age, prior bisphosphonate use and a history of fracture in the last 12 months before starting teriparatide
cCompared with 0 to <6 months interval
Osteoporos Int (2011) 22:2709–2719 2713−2.89 mm (95% CI −3.07 to −2.71; p<0.001); a fracture in
the past 12 months before treatment start was associated with
a greater improvement in back pain of −2.49 mm (95%
CI −4.43 to −0.56; p=0.012) versus no fracture in the past
12 months; whereas each additional historical fracture was
associated with less improvement in back pain of 1.10 mm
(95% CI 0.61 to 1.58; p<0.001).
The results from the back pain questionnaire for the total
study cohort are summarised in Table 3. Both the frequency
and severity of back pain decreased during teriparatide
treatment and this was maintained after teriparatide was
discontinued. At every post-baseline visit, there were
significantly more patients who reported a decrease com-
pared with an increase in the frequency of back pain relative
to baseline (sign test, p<0.001). The same was true for the
severity of back pain (sign test, p<0.001). The limitations on
activities and days in bed due to back pain decreased during
the teriparatide treatment and were then maintained in the
18-month post-teriparatide period (Table 3).
Post-teriparatide cohort
This subgroup consisted of 909 patients who discontinued
teriparatide treatment between baseline and 18 months, and
returned for at least one post-treatment follow-up visit. The
clinical characteristics of the post-teriparatide cohort were
similar to the total study cohort (data not shown), although
persistence with teriparatide was higher in the post-
teriparatide cohort than in the total study cohort (see Fig. S1).
Inthe post-teriparatide cohort, 50patients(5.5%)sustained
a total of 58 fractures during the 18 months after teriparatide
was discontinued. Of the 50 patients with a fracture, 43
sustained one fracture and seven sustained two or more
fractures. Of the 58 fractures, 15 (25.9%) were clinical
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Fig. 2 Adjusted odds of fracture (95% CI) by fracture type (all
fractures pooled, clinical vertebral, non-vertebral and main non-
vertebral) in each 6-month interval for the total study cohort. Note:
*p≤0.05; **p≤0.01; ***p≤0.001 versus 0 to <6 months; model: log
(OddsofFracture) = 6 month interval + age + prior bisphosphonate use
+ fracture in last 12 months. Models adjusted by age, prior
bisphosphonate use and a history of fracture in the last 12 months
before starting teriparatide. Main non-vertebral fractures includes
forearm/wrist, hip, humerus, leg and ribs
2714 Osteoporos Int (2011) 22:2709–2719vertebral fractures and 43 (74.1%) were non-vertebral
fractures; 30 (51.7%) were main non-vertebral fractures at
the forearm/wrist (n=7), hip (n=6), humerus(n=6), ribs (n=
6), and leg (n=5).
Data from the post-teriparatide cohort showed there was
no evidence of further change in the odds of fracture during
the 18 months after stopping teriparatide. The back pain
results for the post-teriparatide cohort were similar to those
for the total study cohort (data not shown).
Safety
A total of 351 adverse events were spontaneously reported by
the physicians beforediscontinuation of teriparatide. Of these,
121 (34.5%) were serious, 173 (49.3%) were considered
possibly related to study medication, and 22 (6.3%) led to
death.Themostcommonadverseeventsreportedwerenausea
(5.4%) and headache (4.3%), and the most common serious
adverse events were death, transient ischaemic attack (4.1%
each), arrhythmia, myocardial infarction, cerebrovascular
accident, dyspnoea and hypertension (2.5% each).
After discontinuation of teriparatide, 31 adverse events
were reported, all occurring either once or twice. Of these, 22
(71.0%) were serious, five (16.1%) were considered possibly
related to study medication and ten (32.3%) led to death.
Discussion
EFOS is the first observational study to report fracture rates
together with back pain in postmenopausal women with
severe osteoporosis in routine clinical practice both during
teriparatide treatment for up to 18 months, and in the
subsequent 18-month post-teriparatide period, when the
majority of patients took other osteoporosis medications,
mainly bisphosphonates. We observed beneficial effects on
the adjusted odds of fracture during teriparatide treatment,
with no evidence of further change in odds of fracture after
teriparatide was discontinued. The adjusted odds of
sustaining any clinical fracture or a vertebral fracture were
significantly lower after 12 to <18 months of teriparatide
treatment compared with the first 6 months. In addition, the
adjusted odds of non-vertebral fracture were significantly
lower after 24 to <30 months. Patients who had a fracture in
the 12 months before baseline or who were previously
treated with bisphosphonates were more likely to fracture
during the study, probably reflecting the higher risk of
fracture in these two patient subgroups [2]. The reduction in
fractures was accompanied by a reduction in back pain
during teriparatide treatment, with the changes in back pain
being maintained for at least 18 months after teriparatide
was discontinued.
Given the teriparatide reimbursement criteria in the
participant countries, the patients taking part in EFOS had
severe osteoporosis and a very high risk of fracture as
indicated by their low BMD values, high number of
previous fractures and presence of other risk factors at
baseline. Moreover, many patients had chronic co-
morbidities (32.5%) and/or took concomitant medications
(63.8%) that would have prevented them from taking part
in controlled trials. Thus, the information provided by this
observational study complements that provided by the
Fig. 3 Back pain VAS: adjusted mean change (95% CI) from baseline
during and after teriparatide treatment in total study cohort. Data
presented is from MMRM analysis. Model included baseline back pain
VAS score, number of previous fractures, fracture in 12 months before
study entry, age, prior bisphosphonate duration, diagnosis of rheumatoid
arthritis, and visit, where repeated measures were modelled with an
unstructured correlation matrix. The unadjusted mean (SD) back pain
VAS scores at 3, 6, 12, 18, 24, 36 months and end of study (LOCF) were
42.9 (25.0), 38.3 (25.4), 34.6 (25.6), 31.9 (25.5), 32.1 (26.7), 29.3 (26.3)
and 33.5 (27.3) mm, respectively. The unadjusted mean change from
baseline to endpoint was −24.3 (SD 31.9)
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2716 Osteoporos Int (2011) 22:2709–2719phase III pivotal trial [12], and recent randomised con-
trolled studies in postmenopausal women with osteoporo-
sis, which focused on BMD changes with different
sequential therapies after teriparatide [21, 22] and may be
useful for enhancing the management of patients suitable
for treatment with teriparatide in routine care.
Moreover, this is one of the first studies to show the
effectiveness of teriparatide in a large sample of osteopo-
rosis patients receiving sequential therapies; the majority
(73.4%) of patients had been treated with bisphosphonates
before study entry and 70.7% received osteoporosis
medications during the 18-month post-teriparatide period.
A notable finding of our study is that a high percentage
of patients completed their course of teriparatide therapy.
Teriparatide was well tolerated, with few patients discon-
tinuing treatment due to adverse events. Moreover, the
adverse events reported were consistent with current
prescription label information.
In the total study cohort, the odds of fracture were
reduced by 39% at 12 to <18 months of treatment (p=
0.013) compared with the first 6 months of treatment; this
decreased further to 74% at 30 to <36 months (p<0.001).
Our findings in previously treated patients of a reduced risk
of fracture (both clinical vertebral and non-vertebral
fractures) during teriparatide treatment that was unchanged
after teriparatide was discontinued, are consistent with the
results of the randomised placebo-controlled trial [12], and
the observational follow-up to the trial [23, 24].
Our analyses of the fracture results also included data
from patients after they had discontinued teriparatide, an
uncommon approach in observational studies. This post-
teriparatide cohort allowed us to focus more specifically on
what happened to patients after they discontinued teripara-
tide regardless of teriparatide duration.
It has been estimated that about three-quarters of patients
with a clinical vertebral fracture experience chronic pain
[4]. In the EFOS total study cohort, the mean back pain
VAS score was high at baseline (57.8 mm), reflecting the
severity of the disease. We observed a reduction in back
pain during teriparatide treatment that was maintained after
teriparatide was discontinued. The marked reduction in
back pain during the first 3 months of teriparatide therapy is
consistent with a meta-analysis of five randomised con-
trolled trials, which found that the risk of new or worsening
back pain was reduced by 34% after teriparatide treatment
[25], and persisted during 30 months of post-treatment
observational follow-up [26]. These earlier studies used
data on back pain reported spontaneously by patients as an
adverse event. In contrast, our study prospectively and
comprehensively analysed back pain that was subjectively
self-assessed by patients both during and after teriparatide
treatment using a VAS and a specific pain questionnaire
that evaluated back pain frequency and severity as well as
activity limitations due to back pain. These back pain
results must be interpreted with caution because recent
randomised controlled trials have found similar reductions
in pain during the first 3 months in both sham- and
vertebroplasty-treated groups of patients with painful
osteoporotic vertebral fractures [27, 28], although in one
of the studies patients received an injection of local
anaesthetic in the periosteum of the crushed vertebrae
[28]. Moreover, back pain in patients who did not sustain a
fracture during the follow-up period would reduce due to
the natural course of the disease [2].
EFOS provided information on the use of different
osteoporosis medications after the end of teriparatide
treatment in normal clinical practice. The majority of
patients (70.7%) received antiresorptives (primarily
bisphosphonates). Whether it was the long-term pharmaco-
logical effect of teriparatide on bone tissue, the contribution
of this sequential medication, or both that affected the post-
treatment risk of fracture is unclear, but the clinically
relevant finding was that there was no evidence of
deterioration in the odds of fracture or a rebound increase
in back pain after teriparatide was discontinued. Antire-
sorptives such as alendronate, calcitonin and raloxifene
have been reported to reduce back pain in postmenopausal
women with osteoporosis [29–35]. It is unclear why we did
not observe a further decline in back pain after teriparatide
discontinuation when most patients were receiving anti-
resorptives. One possible explanation is that the patients
had already reached a low level of back pain (~30 mm).
Our study has several limitations. First, the results are
specific to postmenopausal women with severe osteoporo-
sis and may not be applicable to other types of patients
receiving teriparatide. Second, we did not determine
morphometric vertebral fractures as X-rays were only
performed in symptomatic patients, so we may have
underestimated the effectiveness in overall risk of vertebral
fracture. Third, we did not gather data on the use of
analgesics during the study. Fourth, the study was not
designed to examine the maintenance of fracture efficacy
after discontinuation of treatment, and the wide CIs show
lack of power to determine fracture efficacy after teripara-
tide treatment was discontinued. Finally, the lack of a
randomised control group prevents determination of the
cause of the observed findings, especially subjective
symptoms, such as back pain.
The strengths of the EFOS study include the prospective
examination of clinical fractures in postmenopausal women
with osteoporosis in real-life clinical practice both during
teriparatide therapy and after teriparatide discontinuation.
We also evaluated changes in pain over time using patient-
completed instruments, thereby gaining the patients’ per-
spective. Our analyses adjusted for factors that may
influence back pain, such as age, baseline level of pain,
Osteoporos Int (2011) 22:2709–2719 2717co-morbid rheumatoid arthritis, prior medication and
fracture history.
In conclusion, this large observational study of post-
menopausal women with severe osteoporosis and with co-
morbidities and co-medication showed that the incidence of
clinical vertebral and non-vertebral fractures was reduced
during 18 months of teriparatide treatment. We observed a
74% decrease in the adjusted odds of fracture in the 30- to
<36-month period compared with the first 6-month period
(p<0.001). The change in back pain occurred quickly, with
the greatest change in the first 3 months of treatment, and
was maintained during the 18-month post-teriparatide
period. Further research is needed to confirm these findings
and to identify the best post-teriparatide treatment strategies
for maintaining or even improving the beneficial effects of
teriparatide therapy in the long term.
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